Alpine Associates Management’s Astria Therapeutics ATXS Stock Holding History

Alpine Associates Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-728,922	Closed	-$9.54M	–	73
2025 Q4	$9.54M	Buy	+728,922	New	+$8.71M	0.63%	41

Alpine Associates Management's ATXS Position: Q1 2026 in Review

Alpine Associates Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 728,922 shares — an estimated $9.54M sold.

Alpine Associates Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $9.54M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Alpine Associates Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Alpine Associates Management sold 728,922 Astria Therapeutics shares in Q1 2026, an estimated $9.54M.
Alpine Associates Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Alpine Associates Management's Astria Therapeutics position peaked at $9.54M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Alpine Associates Management's 13F filing for Q1 2026, filed 21 Apr 2026.